Dr. Dennis J. Hartigan-O'Connor's lab at UC Davis focuses on understanding and improving treatments for HIV infection. The lab investigates how T-cell responses can be harnessed to develop effective vaccines that prevent and control HIV. By exploring the interactions between T-cells and antibodies, the lab aims to innovate new therapeutic approaches that could lead to lasting immune protection against HIV.

Dr. Theodora Hatziioannou's lab at Rockefeller University focuses on understanding how the body's antiviral defenses impact the ability of lentiviruses, like HIV-1, to infect hosts. By studying how specific proteins in the immune system respond to these viruses, her team aims to identify ways that lentiviruses evade detection and resistance. This research is critical for developing better strategies for preventing and treating HIV-related diseases.

Dr. Alan Hauser's lab at Northwestern University focuses on studying the bacterium Pseudomonas aeruginosa, a significant cause of infections in hospitals. The lab uses advanced techniques like genetic analysis to uncover why some strains of this bacterium are more virulent than others. Their research aims to identify new genes that contribute to the severity of infections, which could lead to better treatment options for patients.

Dr. Sophie Helaine's research focuses on understanding how certain bacteria, like Salmonella, survive stressful conditions and become resistant to antibiotics. The lab studies specialized genes called Toxin-Antitoxin systems that help bacteria control their growth in response to threats from the immune system or antibiotics. By exploring how these systems are activated and how they function, the lab aims to uncover new strategies to combat antibiotic resistance and improve treatment for bacterial infections.

Dr. Joao Pereira's research lab at Yale University focuses on understanding how blood cells, particularly immune cells, develop from stem cells in the bone marrow. The lab investigates the complex signaling mechanisms that regulate the balance between cell dormancy and activity, which are crucial for maintaining a healthy immune system. Through a combination of advanced molecular techniques and imaging methods, the team's work aims to uncover new insights into immune disorders and potential therapeutic targets for diseases like cancer.

Dr. Richard Flavell's lab at Yale University focuses on studying Alcoholic Liver Disease (ALD), particularly Alcohol Associated Hepatitis (AAH), using advanced humanized mouse models. These models mimic human liver conditions better than traditional mouse models, allowing researchers to explore cellular interactions and metabolic changes in the liver that contribute to disease. The lab aims to uncover how specific signaling interactions between liver cells and immune cells are involved in AAH to identify potential treatment targets.

Dr. Stephan Menne's lab at Georgetown University focuses on understanding and developing new treatments for chronic hepatitis B virus (HBV) infection. The lab works with woodchucks, natural hosts of a closely related virus, to create models that can help evaluate new anti-HBV drugs and better understand how HBV persists in the body. By modifying either the virus or the woodchuck's immune system, the lab aims to improve the efficiency of HBV infection in these models, which is critical for drug development and ultimately for improving patient outcomes.

Dr. Laura Beretta's lab focuses on improving early detection methods for hepatocellular carcinoma (HCC), a deadly form of liver cancer. By studying patients with cirrhosis, the lab aims to discover effective blood tests and modern imaging techniques to identify HCC earlier, which can greatly enhance treatment options and survival rates. Their work combines innovative biomarker analysis and advanced imaging technologies, including artificial intelligence, to better understand cancer risk and progression.

Dr. Richard J Roller's lab at the University of Iowa focuses on understanding how herpesviruses assemble by examining the interactions between viral proteins. By using innovative techniques such as directed evolution and chimeric viruses, the lab aims to discover critical protein interactions that are essential for viral assembly and could lead to improved viral therapies and vaccines.

The Hill lab at UCLA studies a peculiar type of parasite known as Trypanosoma brucei, which causes a serious illness called sleeping sickness in humans and livestock. Their research focuses on understanding the structure and function of the parasite's flagellum, a tail-like structure crucial for its movement and interaction with its environment. The lab utilizes advanced microscopy techniques to explore how these parasites assemble their flagella and how this knowledge can lead to new ways of treating diseases caused by similar parasites.

Dr. Reinhard Hinterleitner's lab studies celiac disease, focusing on how certain gut protists can help the immune system tolerate gluten. This innovative research looks at the relationship between these protists and immune cells to develop potential treatments for individuals at risk of developing celiac disease. By understanding these interactions, the lab aims to create new therapies that could help prevent food-related immune issues.

Dr. Megan A. O'Connor's lab at the University of Washington focuses on understanding how HIV infection impacts the severity of COVID-19 in immunocompromised individuals. The research investigates the interactions between SARS-CoV-2 and the immune system during HIV infection, with a special emphasis on the microbiome's role in disease progression. By using nonhuman primate models, the lab aims to uncover the mechanisms that lead to severe disease outcomes in patients with both infections, potentially guiding therapeutic strategies.

Dr. Kristina De Paris's lab at UNC Chapel Hill focuses on understanding how to induce effective antibodies against HIV, particularly in infants. Their research investigates the roles of vaccine components and the host’s microbiota in the development of broadly neutralizing antibodies (bNAbs), which are essential for preventing HIV infections. By exploring these mechanisms, the lab aims to enhance vaccine strategies for better immune responses.

Dr. Brian Wigdahl's lab at Drexel University focuses on developing advanced gene editing strategies to combat HIV-1 infection, particularly in the body's various tissue reservoirs, including the brain. By utilizing CRISPR technology, the lab aims to enhance the precision and effectiveness of treatments targeting the diverse strains of HIV found in patients. Their innovative research combines high-throughput biological assays and computational biology to improve gene editing outcomes, ultimately seeking to provide a potential cure for HIV.

Dr. Lena Al-Harthi's lab investigates the complex interplay between HIV and drug abuse, particularly focusing on how substances like methamphetamine affect cognitive health in individuals living with HIV. They utilize innovative humanized animal models to explore how HIV hides in the brain and how it impacts brain function and homeostasis. By studying these mechanisms, the lab aims to develop better strategies for addressing cognitive impairments in HIV-positive drug users.

Dr. Paula M. Cannon's lab focuses on developing innovative gene and cell therapy strategies to create a cure for HIV. The team emphasizes making these treatments safe, effective, and accessible, especially for people living with HIV in low and middle-income countries. They work on advanced techniques involving gene editing tools, stem cell manipulation, and novel delivery methods to enhance the efficacy of HIV therapies.

Dr. Ha Youn Lee's lab at USC focuses on innovative ways to track and prevent HIV infections through advanced genetic techniques. They have developed a cutting-edge method called microdrop HIV sequencing, which helps monitor HIV trends and potential drug resistance more effectively, especially in areas with limited resources. Their research aims to improve public health response to the AIDS epidemic by providing reliable data for interventions.

Dr. Joseph B. Margolick's lab at Johns Hopkins University focuses on understanding HIV infection and its long-term effects on health, particularly among men who have sex with men. The lab contributes to a major study that has been ongoing since 1984, examining both the natural and treated histories of HIV. They aim to deepen our knowledge of how HIV affects aging and related health issues through extensive data collection and collaboration with other research sites.

Dr. John P. Moore's lab focuses on understanding how the immune system can effectively combat HIV-1, the virus that causes AIDS. By studying broadly neutralizing antibodies (bNAbs), the lab aims to improve both vaccine strategies and treatments for HIV-1 infection. The research involves innovative methods to analyze antibody behavior and viral interactions to enhance our knowledge of immunity against HIV-1.

Dr. James L. Riley's lab is focused on innovative therapies for HIV, aiming to develop methods that can not only control but potentially cure the infection. They are working on advanced techniques, including engineered T cells and mRNA lipid nanoparticles, to deliver targeted treatments that can help remove the hidden reservoirs of the virus within the body. This research leverages cutting-edge immune engineering and cell therapy to improve patient outcomes for people living with HIV.